Member Info for Ejackson

It’s a sad statistic Porky9 and on a human level, I have sympathy for those that go on to suffer further and ultimately may pass on.
On a human and business/investment level (in that order) we have a world leading product that can help address the virus. The simple nature of the US is such that it needs the likes of NCYT to get on top of what is amongst their population. We need our partners to push our products as aggressively as possible to assist this process. I hope the Biden administration will want to back products that are proven, accurate and have a quick turnaround. They will be keen to demonstrate they are able to deliver results and quickly so we should be pushing against an open door to assist in this direction.
The update, when it comes, will reveal how NCYT and its partners are connected to this critical market.

Porky9, good point and if GM consults his abacus in the next 24 hours and finds the numbers are better than the consensus of the two brokers, it is entirely possible we might get an RNS to that effect.
Now that would be a nice start to the new year.

I would imagine the Board will be being advised to update the market with a statement as to how we traded up to the 25th Dec so as to flush out any interest that might be sitting on the sidelines and not currently wanting to sign an NDA. The interested parties that have will be able to know exactly how things have gone and it would be a shock if it hadn’t followed the recent trends and been anything other than very positive.
It shouldn’t be too long before things start to take shape and I noted Lombard Odier having another little nibble per today’s RNS.

The below taken from the rejection of the SPD offer back in March 2019.
Interesting to note the value they were suggesting and with everything that has changed so positively since, I would be very interested to know what the Board believes to be the current True Value.
Given it was 8th Dec when we were put up for sale, I would expect an update on progress soon.

Wed, 27th Mar 2019 09:00

Findel plc ("Findel" or the "Group")

Circular Rejecting Offer by Sports Direct International Plc ("Sports Direct")
The Board of Findel, announces that it is today publishing its response circular (the "Response Circular") in relation to the mandatory offer for the entire issued and to be issued share capital of Findel not already owned by Sports Direct at a price of 161 pence per share in cash (the "Offer").
The Board reaffirms its previous statements that the Offer significantly undervalues Findel and its future prospects, and strongly urges all shareholders to take no action and reject the Offer for the reasons outlined below:
· Your Group is a market leading UK online value retailer and a leading supplier of resources and equipment to schools worldwide. Both businesses have significant potential. With a strong management team which continues to deliver on its multi-year transformation plan, your Board believes you should receive the benefit of our investment and enjoy our continued growth
· The Offer of 161p per share is opportunistic and undervalues your Group being at a significant discount to fair value, to the Undisturbed Share Price of 250p and to analyst target prices which range from 300p to 350p
· Findel's recent share price performance does not reflect the underlying financial performance of the Group
· Under its current leadership, your Group continues to execute against its digital-first, value-led strategy, ensuring a sustained track record of financial and operational success
· Control by Sports Direct will have a number of potentially adverse consequences for Findel shareholders including an 8.8% dilution in the value of your shareholdings
· Current trading is strong and the Group re-iterates its Q3 trading statement in which it said that "given the strong performance from Studio in Q3, the Group believes that full-year PBT* is now likely to be towards the upper end of current market expectations" (£26 million to £28 million)

https://www.moreaboutadvertising.com/2020/12/coca-cola-launches-giant-4-2bn-creative-and-media-reviews/

Looks like this is in play. Even a tiny fraction of their $4.2 Bn marketing spend would be transformational here. No doubt MS is coordinating S4’s strategy as we speak.

Frasers RNS today and the resulting rise in SP versus ours.
‘Misunderstood’ actually sums it up pretty well.

I agree in part Skindle.
I think his 37% presence has deterred investment in the past and indeed possible predator interest.
In setting a formal process in motion with the significant backing of Schroeder’s, I am hopeful that true value will finally be unlocked. I don’t believe MA will want to frustrate the process as STU just doesn’t fit his future vision and he would far rather realise the cash to put to use elsewhere.
I would anticipate some leak to the press or even an RNS in the next few weeks outlining what sort of strength of interest has been shown in order to get pencils sharpened as the process moves to the next stage.
On reflection, I also think it’s in the interests of maximising the exit price by keeping the current SP where it is to entice ore players in. II activity after the announcement would suggest they believe this is going to happen and a good uplift in SP, likely.

Blinking predictive text.....unfathomable not unfashionable

Good evening Libero.
All I can say is welcome to the highly frustrating world of STU share ownership.
I have been at a loss as to why the market has not responded more positively in the past on occasions but this time around, it’s simply unfashionable.
With regards to your question on expecting a better reaction without the strategic review, again, I am confounded as it can only be a positive in terms of realising shareholder value, so why only 5% uplift?
We have traded in the low £3’s in a lot worse times so today’s SP is a total disconnect. I can only hope multiple bidders come forward and recognise this and the future opportunity to create substantial value that is being served up on a plate. I suspect foreign interest could be strong with the pound so weak.

...my earlier post ‘The Future’
I never thought I would find myself agreeing with MA, however, today just underscores the markets view on SRG.
Great results, putting the company up for sale with the consent of our two largest shareholders and our SP moves, wait for it, 5%.
An absurd reaction.
I now look forward to seeing how this plays out and the value bidders will attach to the company but more importantly, how MA values it as he has the firmest of grips on the role of Kingmaker in this process. The protracted sale of Newcastle United may give us an insight as to what lies ahead although by a strange quirk of circumstance, MA and I find ourselves on the same side. This does assume that he isn’t interested in buying the company himself but given he could have done so previously for a lot less money, I don’t believe it’s something he wants in his portfolio.His obsession is with distressed companies that have bricks and mortar and we just don’t fit that template.
As for my own thoughts on value, I would like to align my opinion with previous RNS’s released by the company trumpeting Edison’s coverage.
Only time will tell but here’s hoping Stifel receive a number of bids and build up a good head of competitive steam.

....from my last post.

Frozen, I respect your opinion, however, as an excersize, cut and paste your response and insert after how ever many years of AGM statements you wish to go back through and it is possible you may reconsider.
My only axe to grind is lack of delivery/ commercialisation. Once this has been monetised and we have a proven, highly profitable company, they can pay themselves according to delivery until then, this is a well trodden perennial path of akin to ‘trust us, lots of exciting things will happen.... in 6 months plus time’.
Delivery is all that matters here and to date, they have been found repeatedly wanting.

Presumably to be re-categorised today under AOB as CNOO:

Chief No Operations Officer.

The following extracted from Proactive Investors commentary today:

Meanwhile, Quadrise said it has continued to progress opportunities with the intention of reaching agreement as soon as possible for the undertaking of letter of no objection (LONO) trials with major companies in the container and/or bulker markets during 2021. Plans under discussion relate to scheduling and vessel and fuel supply preparations being made during the first half of 2021 to commence LONO testing on the main engines of commercial vessels installed with exhaust gas cleaning systems in the second half of the year.

Lest we forget just how long MAERSK took to expedite their sea trials before the vessel ‘unexpectedly’ (damn those hugely expensive, ineffective radars that one of the biggest shipping lines in the world use....) collided with a buoy bringing everything to a crunching halt.
Applying this previous experience/ timelines involved and assuming the company is still listed, it will be this time next year before any form of an update on progress is released. Add on production at scale timelines should it be positive and we are well into 2022 before the sniff of revenue.
Pre-emoting the question ‘Why are you invested then?’ Simply because at these levels it’s not worth selling and as part of my wider portfolio, I can place this in the ‘hoping for a rabbit out of the hat’ category although continuing the animal metaphors, it may well, sadly, be re-categorised as ‘Pigs might fly’

And that’s all that’s in the RNS.
More delays, more jam tomorrow and everything geared to mid way through 2021, when, oh, we will run out of money...
Difficult to see when this will ever become commercially viable. If we saw an SP that was aligned to LONO’s, Exciting discussions with Partners, Extended testing periods etc etc we would be at £1+
I really hope MK and others get quizzed to the point of justified embarrassment today.
Sadly I am unable to tune in to see what unfolds.

With the Mondalez contract announced, which in all probability is a ‘Whopper’ and possibly the one MS referenced in the Q3 results as going to be announced in December ( could there be another one in the offing given we are November?) and that would result in the 2021 budget being revised, I think we can be looking forward to 2021 with justified optimism.
The revenue from Mondelez will come on immediately into the new calendar year as indeed will the T Mobile account, so we have a good head of steam going into 2021 aligned to really positive sentiment from the Board surrounding mergers and further new business.
I am really enjoying the ride here and feel we will be handsomely rewarded over the next few years.

Today simply underlined how NCYT is open to sentiment and MM’s playing on the situation.
The swings in the SP are, in part, predictable as news flow surrounding vaccines come into play and in basic terms, testing becomes ‘ yesterday’s news’.
The reality could not be further from the truth. Testing is still vital and needed, we have the right product and many more relevant to offer and come in the pipeline.
We largely know the revenue involved although, to be fair this is a moving target so only when w3 receive a full RNS will we know.
In the meantime, our Board have a full and clear understanding of what NCYT has, the interest being shown, the orders being placed and the resulting bank. Make no mistake, these people are not boffins with no financial acumen. They are seasoned investors. DYOR. They have invested and backed their products to succeed in a profitable fashion in the future. This is NOT some pie in the sky pot of gold at the end of the rainbow company. They are clever, proven, well respected, profit making investing in themselves individuals. For me, that is compelling and all the gyrations in the SP are down to market irrationality.
The truth will be reported soon and that is all that matters.

Good interview, reads well and if it plays out as he anticipates, we are in for an exciting ride.
Given MS’s commitment, when pressed in the Q3 Q&A session, there will be an RNS before YE on a new Whopper which should lead to a re-rating.

100% agreed Yogi.
The SP is being driven by sentiment which has changed with the Vaccine announcements.
In the meantime, the reality is that we have ramped up the PCR supply side by a factor of 5 and that is to the exclusion of everything else NCYT is involved in and potentially without official confirmation of Phase 2 from UK Gov which if you pause to think about for a moment, could make the numbers involved quite extraordinary.
With news, sentiment will swing back again, it’s just a matter of time.

I am very happy to be guided by our Board and a consultant buying at the levels they did last week.
They have the knowledge of what is going on both developmentally and by way of revenue and then apply a True Value to the company as they see it.
The markets, as has been demonstrated again today, will choose to have its fun and play on sentiment.
Testing is not going to stop in the foreseeable future, indeed, less popular headlines with the MM’s tell us this being massively increased.
Keep to the facts, we know what we have by product range, efficacy, demand from global buyers and supply from our most recent acquisition being ramped up five fold to name just a small handful of reasons to be invested.
On the speculative side, with every day that passes, it is clear that NCYT is developing a larger range of relevant products not just limited to COVID that appear to be way over and above what Big Pharma seems to be rolling out, so it is not inconceivable that we are on the receiving end of a bid that solves an R&D gap for a cash rich company. At these prices, their corporate advisors must, at a minimum, be running the slide rule under NCYT and today’s RNS gives them further insight into what is being achieved. It is also quite an eye opener to read the CV’s of our Board and note how they have all been extensively involved in building companies and then selling having created shareholder value. All speculative musings but it wouldn’t surprise me if it became reality.